These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

552 related items for PubMed ID: 29172796

  • 1. Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance.
    Song J, Ruan X, Gu M, Wang L, Wang H, Mueck AO.
    Gynecol Endocrinol; 2018 May; 34(5):413-417. PubMed ID: 29172796
    [Abstract] [Full Text] [Related]

  • 2. Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients.
    Ruan X, Song J, Gu M, Wang L, Wang H, Mueck AO.
    Arch Gynecol Obstet; 2018 Jun; 297(6):1557-1563. PubMed ID: 29602978
    [Abstract] [Full Text] [Related]

  • 3. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
    Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS.
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3161-8. PubMed ID: 10999803
    [Abstract] [Full Text] [Related]

  • 4. Exploring the significance of sex hormone-binding globulin examination in the treament of women with polycystic ovarian syndrome (PCOS).
    Lin XF, Wu RR, Du J, Liao YC, Du Y, Ye Y, Wang Y, Zhang XB, Wu C, Chen A.
    Clin Exp Obstet Gynecol; 2015 Sep; 42(3):315-20. PubMed ID: 26152001
    [Abstract] [Full Text] [Related]

  • 5. Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses.
    Luque-Ramírez M, Alvarez-Blasco F, Botella-Carretero JI, Sanchón R, San Millán JL, Escobar-Morreale HF.
    Diabetes Care; 2007 Sep; 30(9):2309-13. PubMed ID: 17536071
    [Abstract] [Full Text] [Related]

  • 6. [Effects of orlistat and metformin on metabolism and gonadal function in overweight or obese patients with polycystic ovary syndrome].
    Zhao YX, Wang LJ, Gong FY, Pan H, Miao H, Duan L, Yang HB, Zhu HJ.
    Zhonghua Nei Ke Za Zhi; 2021 Dec 01; 60(12):1165-1168. PubMed ID: 34856689
    [Abstract] [Full Text] [Related]

  • 7. Disparate effects of pharmacotherapy on plasma plasminogen activator inhibitor-1 levels in women with the polycystic ovary syndrome.
    Koiou E, Tziomalos K, Katsikis I, Delkos D, Tsourdi EA, Panidis D.
    Hormones (Athens); 2013 Dec 01; 12(4):559-66. PubMed ID: 24457404
    [Abstract] [Full Text] [Related]

  • 8. Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome.
    Cho LW, Kilpatrick ES, Keevil BG, Coady AM, Atkin SL.
    Clin Endocrinol (Oxf); 2009 Feb 01; 70(2):233-7. PubMed ID: 18547343
    [Abstract] [Full Text] [Related]

  • 9. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J, Zhu Y, Jiang Y, Cao Y.
    Gynecol Endocrinol; 2008 Jul 01; 24(7):392-8. PubMed ID: 18608522
    [Abstract] [Full Text] [Related]

  • 10. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin.
    Feng W, Jia YY, Zhang DY, Shi HR.
    Gynecol Endocrinol; 2016 Jul 01; 32(2):147-50. PubMed ID: 26507097
    [Abstract] [Full Text] [Related]

  • 11. [Effect of 6-month treatment with oral antiandrogen alone and in combination with insulin sensitizers on body composition, hormonal and metabolic parameters in women with polycystic ovary syndrome (PCOS) in order to determine therapeutic strategy].
    Orbetsova M, Kamenov Z, Kolarov G, Zakharieva S, Khristov V, Atanasova I, Shigarminova R, Milcheva B, Genchev G.
    Akush Ginekol (Sofiia); 2006 Jul 01; 45(7):16-28. PubMed ID: 17489164
    [Abstract] [Full Text] [Related]

  • 12. Metabolic profile of Diane-35 versus Diane-35 plus metformin in Chinese PCOS women under standardized life-style changes.
    Wu H, Ruan X, Jin J, Mueck AO.
    Gynecol Endocrinol; 2015 Jul 01; 31(7):548-51. PubMed ID: 26004979
    [Abstract] [Full Text] [Related]

  • 13. The effects of metformin or orlistat on obese women with polycystic ovary syndrome: a prospective randomized open-label study.
    Ghandi S, Aflatoonian A, Tabibnejad N, Moghaddam MH.
    J Assist Reprod Genet; 2011 Jul 01; 28(7):591-6. PubMed ID: 21484319
    [Abstract] [Full Text] [Related]

  • 14. Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome.
    Esfahanian F, Zamani MM, Heshmat R, Moini nia F.
    J Obstet Gynaecol Res; 2013 Apr 01; 39(4):806-13. PubMed ID: 23279603
    [Abstract] [Full Text] [Related]

  • 15. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
    Panidis D, Farmakiotis D, Rousso D, Kourtis A, Katsikis I, Krassas G.
    Fertil Steril; 2008 Apr 01; 89(4):899-906. PubMed ID: 17980364
    [Abstract] [Full Text] [Related]

  • 16. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.
    Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS.
    J Clin Endocrinol Metab; 2003 Jan 01; 88(1):148-56. PubMed ID: 12519844
    [Abstract] [Full Text] [Related]

  • 17. Diet, physical exercise and Orlistat administration increase serum anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome (PCOS).
    Vosnakis C, Georgopoulos NA, Rousso D, Mavromatidis G, Katsikis I, Roupas ND, Mamali I, Panidis D.
    Gynecol Endocrinol; 2013 Mar 01; 29(3):242-5. PubMed ID: 23194076
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of Chinese patent medicine Tian Gui Capsule in patients with polycystic ovary syndrome: a randomized controlled trial.
    Kuek S, Wang WJ, Gui SQ.
    Zhong Xi Yi Jie He Xue Bao; 2011 Sep 01; 9(9):965-72. PubMed ID: 21906521
    [Abstract] [Full Text] [Related]

  • 19. Effect on the cardiovascular independent risk factor lipoprotein(a) in overweight or obese PCOS patients with ethinyl-estradiol/drospirenone alone or plus orlistat.
    Gu M, Ruan X, Li Y, Li T, Yin C, Mueck AO.
    Gynecol Endocrinol; 2022 Jul 01; 38(7):598-602. PubMed ID: 35616272
    [Abstract] [Full Text] [Related]

  • 20. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome.
    Diamanti-Kandarakis E, Katsikis I, Piperi C, Alexandraki K, Panidis D.
    Clin Endocrinol (Oxf); 2007 Jan 01; 66(1):103-9. PubMed ID: 17201808
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.